This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
CHARM-Alternative was a randomized, double-blind, parallel phase 3 treatment trial evaluating candesartan compared with placebo in congestive heart failure.
| Feature | CHARM-Alternative |
|---|---|
| Title | Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Alternative) |
| Status | COMPLETED |
| Design | Randomized, parallel, double-blind |
| Primary purpose | TREATMENT |
| Lead sponsor | AstraZeneca |
| Comparator | Candesartan versus placebo |
2. Clinical Question
Population
Patients with congestive heart failure.
Intervention
Candesartan.
Comparator
Placebo.
Primary question
Does candesartan affect cardiovascular mortality or hospitalisation due to congestive heart failure compared with placebo?
3. Trial Design
Randomized
Double
Parallel
Primary completion date: 2003-05
Candesartan
Drug intervention arm.
Placebo
Drug placebo comparator arm.
4. Endpoints
| Endpoint | Time frame |
|---|---|
| Cardiovascular mortality or hospitalisation due to congestive heart failure | 2, 4, 6 weeks, 6 months, every 4 months thereafter until 24 months |
5. Planned Analysis
The ClinicalTrials.gov record identifies the primary endpoint as a cardiovascular mortality or congestive heart failure hospitalization outcome assessed over follow-up visits extending until 24 months.
For a time-to-event composite endpoint of this type, statistical analysis typically focuses on comparing the time until the first occurrence of a qualifying event between randomized groups. Common approaches include survival curves, hazard-based comparisons, confidence intervals around relative treatment effects, and evaluation of censoring assumptions.
6. Statistical Methodology
Composite endpoints
The primary endpoint combines cardiovascular mortality and hospitalization due to congestive heart failure. Composite endpoints allow multiple clinically important outcomes to be evaluated together, but interpretation depends on understanding how each component contributes to the overall result.
Time-to-event analysis
When an endpoint measures time until the first event, patients without an observed event during follow-up may contribute censored information. Methods such as Kaplan-Meier estimation and Cox proportional-hazards modeling are commonly used for these analyses.
Randomization
Random allocation helps balance known and unknown prognostic factors between treatment groups, allowing differences in outcomes to be attributed more directly to the assigned intervention.
7. Statistical Methods Explained
Why is randomization important in this trial?
Randomization creates comparable treatment groups at baseline. This reduces bias when estimating differences between candesartan and placebo.
Why analyze cardiovascular mortality and hospitalization together?
A composite endpoint can capture more total clinical events, but interpretation requires understanding whether both components contribute meaningfully to the observed comparison.
Why are time frames specified for endpoint assessment?
Prespecified assessment windows define when outcome information is collected and help maintain consistency in endpoint evaluation.
What does double masking contribute?
Double masking reduces the possibility that knowledge of treatment assignment influences patient care, reporting, or outcome assessment.
Why use survival methods?
Survival methods account for differences in follow-up duration and allow patients with incomplete event observation to contribute available information.
8. Limitations
- The ClinicalTrials.gov record does not report posted statistical analyses or outcome estimates.
- Without posted results, treatment effects and uncertainty estimates cannot be evaluated from the registry record alone.
- Composite endpoints require interpretation of both the overall endpoint and the individual clinical events contributing to it.
- Time-to-event analyses depend on assumptions regarding censoring and model specification.
9. Why This Trial Matters Statistically
| Concept | How it appears in CHARM-Alternative |
|---|---|
| Randomized design | Patients were assigned in a randomized comparison. |
| Blinding | Double masking was used. |
| Parallel groups | Two-arm parallel design. |
| Composite endpoint | Cardiovascular mortality or hospitalisation due to congestive heart failure. |
| Longitudinal follow-up | Assessments continued until 24 months. |